2007
DOI: 10.1016/j.brainresrev.2007.08.002
|View full text |Cite
|
Sign up to set email alerts
|

Protease-activated receptors in the brain: Receptor expression, activation, and functions in neurodegeneration and neuroprotection

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
131
1
1

Year Published

2008
2008
2017
2017

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 148 publications
(134 citation statements)
references
References 145 publications
1
131
1
1
Order By: Relevance
“…This possible dual effect of thrombin has been alluded to recently [Luo et al (2007) and references therein] and is a subject for further experimentation.…”
Section: Discussionmentioning
confidence: 80%
“…This possible dual effect of thrombin has been alluded to recently [Luo et al (2007) and references therein] and is a subject for further experimentation.…”
Section: Discussionmentioning
confidence: 80%
“…PAR are characterized by the presence of a tethered peptide ligand in their N‐terminal part which, when released by cleavage, acts on the ligand binding site and activates the receptor. The expression of PAR in the brain is differentially regulated in neurodegenerative disorders like PD, AD, multiple sclerosis and stroke (Luo, Wang, & Reiser, 2007). Activation of PAR can lead to cell death or cell survival, depending on the magnitude and the duration of agonist stimulation.…”
Section: Potential Therapeutic Targets In Astrocytesmentioning
confidence: 99%
“…Cong Lin, 1 Jan von der Thüsen, 2 Joost Daalhuisen, 1 Marieke ten Brink, 1 Bruno Crestani, 3 Tom van der Poll, acute/chronic inflammatory and fibrotic diseases of the joints, skin, brain, lung and gastrointestinal tract (10,(12)(13)(14)(15).With respect to lung injury and pulmonary fibrosis, there is increasing evidence that PAR-2 is a critical contributor in the pathogenesis of IPF. Increased PAR-2 expression has been detected in the lungs of patients with IPF, and a recent study proposed that the PAR-2/tissue factor (TF)/FVIIa axis may contribute to the development and/or progression of IPF (16).…”
Section: Pharmacological Targeting Of Protease-activated Receptor 2 Amentioning
confidence: 99%